Skip to main content
Publications
Pe M, Alanya A, Falk RS, Amdal CD, Bjordal K, Chang J, Cislo P, Coens C, Dirven L, Speck RM, Fitzgerald K, Galinsky J, Giesinger JM, Holzner B, Le Cessie S, O'Connor D, Oliver K, Pawar V, Quinten C, Schlichting M, Ren J, Roychoudhury S, Taphoorn MJB, Velikova G, Wintner LM, Griebsch I, Bottomley A, SISAQOL-IMI Consortium. Setting international standards in analyzing patient-reported outcomes and quality of life endpoints in cancer clinical trials-innovative medicines nitiative (SISAQOL-IMI): stakeholder views, objectives, and procedures. Lancet Oncol. 2023 Jun;24(6):e270-83. doi: 10.1016/S1470-2045(23)00157-2
Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L, Wang J, Pan JJ, Saretsky TL, Perini RF, He CS, Mody K, Cella D. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet Oncol. 2022 Jun;23(6):768-80. doi: 10.1016/S1470-2045(22)00212-1
Polanska K, Kaluzny P, Aubert AM, Bernard JY, Duijts L, El Marroun H, Hanke W, Hebert JR, Heude B, Jankowska A, Mancano G, Mensink-Bout SM, Relton C, Shivappa N, Suderman M, Trafalska E, Wesolowska E, Garcia-Esteban R, Guxens M, Casas M, Phillips CM. Dietary quality and dietary inflammatory potential during pregnancy and offspring emotional and behavioral symptoms in childhood: an individual participant data meta-analysis of four European cohorts. Biol Psychiatry. 2021 Mar 15;89(6):550-9. doi: 10.1016/j.biopsych.2020.10.008
Phiri K, Hallas J, Linder M, Margulia A, Suehs B, Arana A, Bahmanyar S, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Sahlertz Kristiansen N, Appenteng K, de Vogel S, Seeger J. A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder. Poster presented at the American Urological Association 2020 Conference (Conference cancelled); May 2020. Washington, DC. [abstract] J Urol. 2020 Apr; 203(Supplement 4):e910-1. doi: 10.1097/JU.0000000000000931.010
Mease P, Gladman D, Davenport E, Zhou X, Guerette B, Teng L, Kaura S, Nash P. Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomized, controlled study in biologic-naïve subjects with active psoriatic arthritis. Poster presented at the 37th Scandinavian Congress of Rheumatology; September 5, 2018. Helsinki, Finland. [abstract] Scand J Rheumatol. 2018 Sep 5; 47(Suppl 129):34-5. Previously presented at the 2017 ACR/ARHP Annual Meeting.